Recombinant Human IL-29/IFN-lambda 1

Molecule:

IL-29

Synonyms:

Interferon lambda-1, Interleukin-29, IL29, IFNL1, IFN-lambda-1, IL-29

Species:

Human

Cat. No.:

CRI010C pdf (datasheet)

Quantity/Size:

1.0 mg

Price:

$2,700.00 / Special Price: $1,640.00 BUY

Description:

Recombinant Human IL-29/IFN-lambda 1 is a single non-glycosylated polypeptide chain containing 181 amino acids. Background: IL-28A, IL-28B, and IL-29, also named interferon-λ2 (IFN-λ2), IFN-λ3, and IFN-λ1, respectively, are newly identified class II cytokine receptor ligands that are distantly related to members of the IL-10 family (11-13 % a.a. sequence identity) and the type I IFN family (15-19 % a.a. sequence identity). The expression of IL-28A, B, and IL-29 is induced by virus infection or double-stranded RNA. All three cytokines exert bioactivities that overlap those of type I IFNs, including antiviral activity and up-regulation of MHC class I antigen expression. The three proteins signal through the same heterodimeric receptor complex that is composed of the IL-10 receptor β (IL-10 Rβ) and a novel IL-28 receptor α (IL-28 Rα, also known as IFN-λR1). Ligand binding to the receptor complex induces Jak kinase activation and STAT1 and STAT2 tyrosine phosphorylation.

Data PDF:

CRI010

Source:

E. coli

Molecular Weight:

~19.8 kDa

Formulation:

Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4.

Purity:

>97 % by SDS-PAGE and HPLC analyses.

Biological Activity:

Fully biologically active when compared to standard. The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis is less than 5 ng/ml, corresponding to a specific activity of >2.0 × 105 IU/mg.

Endotoxin Level:

Less than 1EU/μg as determined by LAL method.

Amino Acid Sequence:

GPVPTSKPTT TGKGCHIGRF KSLSPQELAS FKKARDALEE SLKLKNWSCS SPVFPGNWDL RLLQVRERPV ALEAELALTL KVLEAAAGPA LEDVLDQPLH TLHHILSQLQ ACIQPQPTAG PRPRGRLHHW LHRLQEAPKK ESAGCLEASV TFNLFRLLTR DLKYVADGNL CLRTSTHPES T

Reconstitution:

Centrifuge vial prior to opening. Add sterile distilled water or aqueous buffer to a concentration of 0.1-1.0 mg/mL. Further dilutions should be made in appropriate buffered solutions.

Storage/Stability:

This lyophilized preparation is stable at 2-8°C, but should be kept desiccated at -20°C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-8°C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -80°C. Avoid repeated freeze/thaw cycles.